737789-87-6
737789-87-6 structure
- Name: Relugolix
- Chemical Name: 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea
- CAS Number: 737789-87-6
- Molecular Formula: C29H27F2N7O5S
- Molecular Weight: 623.63
- Catalog: Signaling Pathways GPCR/G Protein GNRH Receptor
- Create Date: 2018-06-03 08:00:00
- Modify Date: 2026-07-02 02:07:48
-
Relugolix is a novel, non-peptide, orally active gonadotropin-releasing hormone (GnRH) antagonist with IC50 of 0.33 nM in the presence of 40% fetal bovine serum, TAK-385 possesses higher affinity and potent antagonistic activity compared with TAK-013.target: GnRH [1]IC50: 0.33 nM [1]In vivo: In female knock-in mice, twice-daily oral administration of TAK-385 (100mg/kg) induces constant diestrous phases within the first week, decreases the uterus weight to ovariectomized levels and downregulated GnRH receptor mRNA in the pituitary after 4 weeks.[2]
| Name | 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea |
|---|---|
| Synonyms |
2H6]-RVT-601
ethyl 5-(4-aminophenyl)-2-((2,6-difluorobenzyl)(ethoxycbonyl)amino)-4-((dimethylamino)methyl)thiophene-3-cboxylate Rui Lugoli 10G,G,G Cefime hydrochloride anhydrous TAK-385;TAK 385;TAK RVT-601|||TAK-385 Urea, N-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy TAK-385 RVT-601 Relugolix Impurity 17 TKA-385 Relugolix ruiugoli A60%,B Relugolix (1-[4-[1-[(2,6-difluorophenyl)methyl]-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea) N-[4-[1-[(2,6-Difluorophenyl)methyl]-5-[(dimethylamino)methyl]-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxy urea Relugoli N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenylcbamoyl)-N-methoxybutyramide Altropane 1-[4-[1-[(2,6-difluorophenyl)methyl]-5-(dimethylaminomethyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-6-thieno[4,5-e]pyrimidinyl]phenyl]-3-methoxyurea TAK-385,Relugolix Relugolix(NEC-1) Rui Lu Geli 1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydro thieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxy urea, Relugolix Relugolix TAK-385 Relugolix, 10 mM in DMSO |
| Description | Relugolix is a novel, non-peptide, orally active gonadotropin-releasing hormone (GnRH) antagonist with IC50 of 0.33 nM in the presence of 40% fetal bovine serum, TAK-385 possesses higher affinity and potent antagonistic activity compared with TAK-013.target: GnRH [1]IC50: 0.33 nM [1]In vivo: In female knock-in mice, twice-daily oral administration of TAK-385 (100mg/kg) induces constant diestrous phases within the first week, decreases the uterus weight to ovariectomized levels and downregulated GnRH receptor mRNA in the pituitary after 4 weeks.[2] |
|---|---|
| Related Catalog | |
| References |
| Molecular Formula | C29H27F2N7O5S |
|---|---|
| Molecular Weight | 623.63 |
| PSA | 169.36000 |
| LogP | 3.96660 |
| Storage condition | 2-8℃ |